Implications of N-terminal pro-B-type natriuretic peptide in patients with three-vessel disease

• Published in: European heart journal 2019-11, Vol.40 (41), p.3397-3405
• Main Authors: Zhang, Ce, Jiang, Lin, Xu, Lianjun, Tian, Jian, Liu, Junhao, Zhao, Xueyan, Feng, Xinxing, Wang, Dong, Zhang, Yin, Sun, Kai, Xu, Bo, Zhao, Wei, Hui, Rutai, Gao, Runlin, Yuan, Jinqing, Song, Lei
• Format: Article
• Language: English
• ISSN: 0195-668X; 1522-9645
• DOI: 10.1093/eurheartj/ehz394

Abstract Aims Risk assessment and treatment stratification for three-vessel disease (3VD) remain challenging. N-terminal pro-B-type natriuretic peptide (NT-proBNP) is an established biomarker for prognostication and treatment in heart failure. The present study aimed to evaluate the prognostic value of NT-proBNP beyond the SYNTAX score II (SSII), and its association with long-term outcome after three strategies [percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), and medical therapy (MT)] in a cohort of patients with 3VD. Methods and results A total of 6597 patients with available baseline NT-proBNP data were included in the study. Baseline, procedural, and follow-up data were collected. The primary endpoint was all-cause death. Secondary endpoints included cardiac death and major adverse cardiac and cerebrovascular events (MACCE), a composite of death, myocardial infarction, and stroke. During a median follow-up of 7.0 years, higher NT-proBNP levels were strongly associated with increased risks of all-cause death, cardiac death, and MACCE (all adjusted P